Hurrell is a CSIR senior researcher in bioengineering and integrated genomics, working on developing contextualized, advanced three-dimensional cellular liver models, which can guide healthcare initiatives in Africa.

She completed her PhD in pharmacology at the University of Pretoria, while also attending the University of Cambridge as a Commonwealth Scholar. Following her PhD, she spent two years as a postdoctoral researcher in the Section of Pharmacogenetics, Department of Physiology and Pharmacology at Karolinska Institutet in Sweden.

Expertise: Pharmacology and In vitro liver modelling.

More publications

•  Hurrell T#, Naidoo J#, Scholefield J. Hepatic models in precision medicine: an African perspective on pharmacovigilance (#equal contribution). Frontiers in Genetics. Accepted March 2022.​
• Naidoo J#, Hurrell T#, Scholefield J. IPSC-derived models in Africa: An HIV perspective (#equal contribution). Biochimie. 2022 Jan 26.​
• Mulvey CM, Breckels LM, Crook OM, Sanders DJ, Ribeiro ALR, Geladaki A, Christoforou A, Kočevar Britovšek N, Hurrell T, Deery MJ, Gatto L, Smith AM, and Lilley KS. Spatiotemporal proteomic profiling of the pro-inflammatory response to lipopolysaccharide in the THP-1 human leukaemia cell line. Nature communications, 2021; 12(1), 1-19)​
• Ellero AA., van den Bout I, Vlok M, Cromarty AD, Hurrell T. Continual proteomic divergence of HepG2 cells as a consequence of long-term spheroid culture. Sci Rep 2021; 11:10917 (https://doi.org/10.1038/s41598-021-89907-9)​
• Hurrell T#, Kastrinou-Lampou V#, Fardellas A, Hendriks DFG, Nordling Å, Johansson I, Baze A, Parmentier C, Richert L, Ingelman-Sundberg M. Human liver spheroids as a model to study aetiology and treatment of hepatic fibrosis (#equal contribution). Cells. 2020; 9(4) E964 (doi: 10.3390/cells9040964).​
• Hendriks DGF#, Hurrell T#, Riede J, van der Horst M, Tuovinen S, Ingelman-Sundberg M. Mechanistic understanding of fialuridine hepatotoxicity using human hepatic 3D spheroids (#equal contribution). Toxicological Sciences. 2019; 171(2):385–395 (doi: 10.1093/toxsci/kfz195 2019).​
• Morgantini C, Jager J, Li X, Levi L, Sulen A, Barreby E, Xu C, Tencerova M, Näslund E, Kumar C, Verdeguer F, Straniero S, Hultenby K, Bjorkstrom N, Ellis E, Tomčala A, Krejčová G, Bajgar A, Azzimato V, Ryden M, Hurrell T, Lauschke V, Boucher J, Kutter C and Aouadi M. Liver macrophages regulate systemic metabolism through non-inflammatory factors. Nature Metabolism. 2019; 1: 445–459 (doi: 10.1038/s42255-019-0044-9).​
• Hurrell T, Segeritz C.P, Vallier L, Lilley KS, and Cromarty AD. A proteomic time course through the differentiation of human induced pluripotent stem cells into hepatocyte-like cells. Scientific Reports. 2019; 9: 3270 (doi: 10.1038/s41598-019-39400-1).​
• Baze A, Parmentier C, Hendriks DF, Hurrell T, Heyd B, Bachellier P, Schuster C, Ingelman-Sundberg M, and Richert, L. 3D spheroid primary human hepatocytes in mono-culture and co-culture with non-parenchymal cells. Tissue Engineering Part C: Methods. 2018; 24(9):534-45 (doi: 10.1089/ten.TEC.2018.0134.).​
• Hurrell T, Lilley KS, and Cromarty AD. Proteomic responses of HepG2 cell monolayers and 3D spheroids to selected hepatotoxins. Toxicology Letters. 2019; 300:40-50 (doi: 10.1016/j.toxlet.2018.10.030.).​
• Hurrell T, Segeritz C.P, Vallier L, Lilley KS, and Cromarty AD. Proteomic comparison of various hepatic cell cultures for preclinical safety pharmacology. Toxicological Sciences. 2018; kfy084 (doi: 10.1093/toxsci/kfy084).​
• Hurrell T, Ellero A, Masso ZF, Cromarty AD. Characterization and reproducibility of HepG2 hanging drop spheroids. Toxicology In Vitro. 2018; 50:86-94 (doi: 10.1016/j.tiv.2018.02.013).​
• Christoforou A, Mulvey CM, Breckels LM, Geladaki A, Hurrell T, Hayward PC, Naake T, Gatto L, Viner R, Martinez-Arias A and Lilley KS. A draft map of the mouse pluripotent stem cell spatial proteome. Nature Communications. 2016; 7 (doi: 10.1038/ncomms9992).​
• Khwitshana AK, Greeff OBW, Hurrell T. Assessing adherence to the 2010 antiretroviral guidelines in the antiretroviral roll-out clinic at 1 Military Hospital South Africa: A retrospective, cross-sectional study. South African Medical Journal. 2014; 104(7):495­500 (doi: 10.7196/SAMJ.7926).​
• Hurrell T, Outhoff K. The in vitro influences of epidermal growth factor and heregulin-ß1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma. Cancer Cell International. 2013; 13(97):1-9 (doi: 10.1186/1475-2867-13-97).​
• Hurrell T, Outhoff K. Human epidermal growth factor receptor 2 breast cancer: which cytotoxic agent best complements trastuzumab’s efficacy in vitro? OncoTargets and Therapy. 2013; 6:693-701 (doi: 10.2147/OTT.S46883).​